THE SYMPTOMS AND CO-MORBIDITIES OF COVID-19 PATIENTS AT HOME ISOLATION IN INDIA

Year 2021, Volume: 6 Issue: 2, 182 - 189, 27.08.2021

Sujata Murarkar Sudhanshu Mahajan , Jayashree Gothankar

https://doi.org/10.33457/ijhsrp.835756

Cited By: 1

Abstract

Introduction: An Indian Government has issued the guidelines on home isolation for very mild/pre-symptomatic COVID-19 cases based on a proposal of the Directorate of Public Health and Preventive Medicine. This has originated when COVID-19 designated hospitals started to shift asymptomatic and stable patients to quarantine facilities to reserve beds for those in need of treatment.
Objectives: To determine the prevalence of symptoms and co-morbidities of COVID-19 positive patients at home isolation OPD.
Methods: This cross-sectional study was conducted at a designated COVID-19 tertiary care hospital in Pune, India, which had included all COVID-19 positive patients enrolled for the home isolation care from the 15th July to 15th August 2020.
Results: There were total 639 adults out of which 362 were males and 277 females. The most common presenting symptom present in 49.4% cases was fever. Hypertension was the most prevalent comorbidity noticed in 10% of patients followed by Diabetes in 6.7%. The maximum time lag of positive COVID-19 test to registration for home isolation OPD of 8 days was observed in only 1 patient. The significant association was seen between symptom of fever with the adults (males) and in the age group of 31-50 years(p<0.05).
Conclusion: Home isolation could be considered a classic model for COVID-19 patients in resource constrained situation. Home isolation can substantially reduce health care expenses for the asymptomatic and mild symptomatic COVID-19 multitude.

Keywords

Co-morbidities, Home isolation, COVID-19

References

• [1 ] D. S. Hui, E. I. Azhar, T. A. Madani, F. Ntoumi, R. Kock, O. Dar, G. Ippolito, T. D. Mchugh, Z. A. Memish, C. Drosten, A. Zumla, and E. Petersen, “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China,” International Journal of Infectious Diseases, vol. 91, pp. 264–266, 2020.
• [2] “Naming the coronavirus disease (COVID-19) and the virus that causes it,” World Health Organization. [Online]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. [Accessed: 04-Dec-2020].
• [3] “WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020,” World Health Organization. [Online]. Available: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. [Accessed: 04-Dec-2020].
• [4] “WHO-nCov-IPC-HomeCare-2020.3-eng.pdf,” Scribd. [Online]. Available: https://www.scribd.com/document/452982345/WHO-nCov-IPC-HomeCare-2020-3-eng-pdf. [Accessed: 04-Dec-2020].
• [5] “Clinical management of severe acute respiratory infection …” [Online]. Available: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf. [Accessed: 04-Dec-2020].
• [6].https://www.mohfw.gov.in/pdf/RevisedHomeIsolationGuidelines.pdf
• [7] https://www.mohfw.gov.in/pdf/FAQ.pdf
• [8] “Clinical characteristics of COVID-19,” European Centre for Disease Prevention and Control, 08-Sep-2020. [Online]. Available: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical. [Accessed: 04-Dec-2020].
• [9] Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, and B. Cao, “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497–506, 2020.
• [10] M. C. Grant, L. Geoghegan, M. Arbyn, Z. Mohammed, L. Mcguinness, E. L. Clarke, and R. Wade, “The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries,” SSRN Electronic Journal, 2020.
• [11] Lu, J. Lin, Z. Zhang, L. Xiao, Z. Jiang, J. Chen, C. Hu, and S. Luo, “Alert for non‐respiratory symptoms of coronavirus disease 2019 patients in epidemic period: A case report of familial cluster with three asymptomatic COVID‐19 patients,” Journal of Medical Virology, 2020.
• [12] G. Onder, G. Rezza, and S. Brusaferro, “Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy,” Jama, 2020.
• [13] “The COVID-19 Sex-Disaggregated Data Tracker,” Global Health 5050. [Online]. Available: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/. [Accessed: 04-Dec-2020].
• [14] J. Li, D. Q. Huang, B. Zou, H. Yang, W. Z. Hui, F. Rui, N. T. S. Yee, C. Liu, S. N. Nerurkar, J. C. Y. Kai, M. L. P. Teng, X. Li, H. Zeng, J. A. Borghi, L. Henry, R. Cheung, and M. H. Nguyen, “Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes,” Journal of Medical Virology, 2020.
• [15] A. Sanyaolu, C. Okorie, A. Marinkovic, R. Patidar, K. Younis, P. Desai, Z. Hosein, I. Padda, J. Mangat, and M. Altaf, “Comorbidity and its Impact on Patients with COVID-19,” SN Comprehensive Clinical Medicine, vol. 2, no. 8, pp. 1069–1076, 2020.
• [16] J. Yang, Y. Zheng, X. Gou, K. Pu, Z. Chen, Q. Guo, R. Ji, H. Wang, Y. Wang, and Y. Zhou, “Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis,” International Journal of Infectious Diseases, vol. 94, pp. 91–95, 2020.
• [17] D. P. Oran and E. J. Topol, “Prevalence of Asymptomatic SARS-CoV-2 Infection,” Annals of Internal Medicine, vol. 173, no. 5, pp. 362–367, 2020.
• [18] Z.H. Feng, Y. R. Cheng, L. Ye, M. Y. Zhou, M. W. Wang and J. Chen, “Is home isolation appropriate for preventing the spread of COVID-19?,” Public Health, vol. 183, pp. 4-5, 2020